What Happens to Your Body Week by Week on Ozempic

The first 48 hours: what's happening in your body

The short answer: a lot, even if the scale doesn't show it yet. Semaglutide — the active ingredient in Ozempic — binds to GLP-1 receptors throughout the body, and the gut is the first place this becomes obvious.

Within 24–48 hours of your first 0.25mg injection, gastric emptying begins to slow. Food moves from your stomach to the small intestine more gradually than it did before. The result: meals feel more filling, faster. You may eat half your plate and feel genuinely done — not because you're trying to eat less, but because the satiety signal arrives earlier and stays longer.

Nausea is common at this stage, affecting roughly 15–20% of users at the starting dose. It typically arrives 1–4 hours after injection and is usually described as mild to moderate. The mechanism is the same — slowed gastric emptying means food and stomach acid sit in contact longer. For most people, this eases significantly once the body adapts. Avoiding high-fat, highly seasoned meals in the first few days reduces the severity.

Weeks 1–4: appetite starts shifting

The most reported experience during the first four weeks is not dramatic weight loss — it's a change in the relationship with food. "Food noise" — the constant mental background chatter about what to eat, when to eat, cravings for specific foods — begins to quiet for many users. This is the GLP-1 receptor action in the brain, not just the gut.

At 0.25mg (the starting dose), the pharmacological effect is intentionally gentle. The dose is low enough to allow the body to adapt while minimising side effects. Significant weight loss at this stage is not the goal and is not typical. Average weight loss by week 4 at 0.25mg is approximately 1–2kg, largely driven by reduced caloric intake rather than any metabolic change.

Something less expected that many users notice in this window: cravings for alcohol and ultra-processed food drop noticeably. A 2023 study in Nature Medicine found that GLP-1 receptor agonists reduced alcohol use disorder symptoms — an early hint at the drug's broader effects on reward pathways, not just hunger.

• Nausea: typically peaks in week 1–2, then starts improving
• Appetite: reduced at meals; "food noise" decreasing for many users
• Weight change: minimal at this stage (0.25mg dose is a titration dose)
• Cravings: alcohol and junk food cravings often reduce earlier than expected

Weeks 5–12: the dose escalates, weight starts moving

Standard titration protocol moves users to 0.5mg at week 5. For many, this is when the effect becomes unmistakable. Appetite suppression deepens, portion sizes shrink further, and the scale begins to move consistently.

At week 9, most patients who tolerate 0.5mg well are escalated to 1mg — the primary therapeutic dose for type 2 diabetes management. For weight loss, some protocols continue escalation to 2mg. In the SUSTAIN 1 trial, patients at 1mg lost an average of 4.6kg at 30 weeks. By week 12 specifically, the range in clinical settings is approximately 3–6kg depending on adherence, diet, and baseline weight.

This is also the window where non-scale changes become measurable. Blood glucose levels improve (particularly fasting glucose and post-meal spikes), blood pressure begins dropping in many users, and energy levels often improve as overall caloric load decreases and glycaemic variability reduces.

Months 3–6: full therapeutic effect

By month 3, most users are at their maintenance dose — either 1mg or 2mg depending on their protocol. This is when the cumulative effect of sustained appetite reduction and reduced caloric intake translates into meaningful body composition changes.

The STEP 1 trial (using 2.4mg semaglutide weekly, the Wegovy dose) reported an average 14.9% body weight reduction at 68 weeks. At the 1mg Ozempic dose, real-world and clinical data suggests 8–12% total body weight loss over 6 months for adherent users — roughly 8–12kg for a person starting at 100kg.

Beyond weight, changes at this stage include:

• Blood pressure: systolic reductions of 3–5 mmHg are commonly reported in clinical data
• HbA1c: significant reductions in people with type 2 diabetes (the drug's primary indication)
• Energy: many users report meaningful improvements in daily energy and reduced fatigue
• Inflammation markers: CRP and other inflammatory markers trend downward with weight loss

To check whether your medication is having the expected effect, see our guide on how to know if Ozempic is working for you.

Beyond 6 months: long-term changes and what to watch

For users who remain on Ozempic beyond 6 months, weight loss typically plateaus. This is normal and expected — not a sign of tolerance. The body finds a new equilibrium at a lower weight, and the drug maintains that equilibrium rather than driving continued loss indefinitely.

The key risk at this stage is muscle loss. Any significant caloric deficit causes some lean mass loss, and fast weight loss accelerates it. Studies on GLP-1 drugs suggest that without deliberate intervention (resistance training, adequate protein), 25–40% of weight lost can be lean mass rather than fat. Read our full guide on preventing muscle loss on GLP-1 medications to understand what the evidence recommends.

Other things to monitor beyond 6 months:

• "GLP-1 face": rapid facial fat loss that can cause a gaunt appearance — a cosmetic concern, not a health risk, but worth being aware of if losing weight quickly
• Mental health: some studies report improvements in depression and anxiety symptoms with weight loss and GLP-1 use; individual responses vary
• Sustainability: the question of whether and how long to stay on the medication is important to discuss with your prescribing doctor; weight regain after stopping is significant (see STEP 4 trial data)

FAQ

Medical disclaimer: This article is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional before making changes to your medication, diet, or exercise routine.